HealthEquity
HQY
94.75
-2.63
-2.70%
HealthEquity
US · HQY
#1726 by market cap
Listed 1970
94.75
-2.63
-2.70%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 17 in the most recent period (2026/Q3).
- Total institutional ownership rose 6.9 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 117.08% +6.90pp
- Institutions
- 621 +17
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund95.44%
Hedge Fund8.78%
Public Company6.79%
Private Company2.25%
Individual/Insider2.07%
Government Pension Fund1.93%
Sovereign Wealth Fund0.69%
Insurance Company0.53%
Family Office/Trust0.47%
Top holders as of 2026-09-30
BlackRock
13.66% · 11.30M sh
Wasatch Advisors LP
8.48% · 7.01M sh
Vanguard Portfolio Management, LLC
4.78% · 3.95M sh
Morgan Stanley Investment Management Inc.
4.60% · 3.81M sh
Morgan Stanley
4.60% · 3.81M sh
Vanguard Capital Management, LLC
4.32% · 3.58M sh
State Street Global Advisors
3.92% · 3.24M sh
Eaton Vance Management
2.94% · 2.43M sh
Dimensional Fund Advisors
2.26% · 1.87M sh
Geode Capital Management, LLC
2.81% · 2.33M sh
AQR Capital Management
2.41% · 1.99M sh
William Blair Investment Management, LLC
2.20% · 1.82M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 18 buys · 29 sells
| Name | Role | Stake |
|---|---|---|
| Stephen Neeleman | Founder & Vice Chairman | 1.04% |
| Jon Kessler | Former Director & Special Advisor | 0.40% |
| Robert Selander | Independent Non-Executive Chairperson | 0.11% |
| Elimelech Rosner | Former Chief Technology Officer | 0.10% |
| Adrian Dillon | Independent Director | 0.07% |
| Delano Ladd | General Counsel | 0.07% |
| Sunil Rajasekar | Executive VP and Chief Product & Strategy Officer | 0.06% |
| Evelyn Dilsaver | Independent Director | 0.06% |
| James Lucania | Chief Financial Officer | 0.05% |
| Scott Cutler | Chief Executive Officer | 0.03% |
| Stuart Parker | Independent Director | 0.03% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-14 | Sunil Rajasekar | Executive VP and Chief Product & Strategy Officer | Open Market Acquisition | +131 | $90.33–95.06 |
| 2026-10-05 | James Lucania | Chief Financial Officer | Sale to Issuer | -2,822 | $91.16 |
| 2026-10-05 | Stephen Neeleman | Founder & Vice Chairman | Sale to Issuer | -1,095 | $91.16 |
| 2026-10-05 | Scott Cutler | Chief Executive Officer | Sale to Issuer | -1,230 | $91.16 |
| 2026-10-05 | Delano Ladd | General Counsel | Sale to Issuer | -1,080 | $91.16 |
| 2026-10-05 | Michael Fiore | Former Executive Vice President | Sale to Issuer | -2,032 | $91.16 |
| 2026-10-05 | Michael Gathright | -- | Sale to Issuer | -662 | $91.16 |
| 2026-09-23 | Noemie Heuland | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-09-16 | Stephen Neeleman | Founder & Vice Chairman | Other Disposition | -1,500 | -- |
| 2026-08-24 | Adrian Dillon | Independent Director | Derivative Exercise and Sale | -7,632 | $32.50–105.26 |
| 2026-08-23 | Sunil Rajasekar | Executive VP and Chief Product & Strategy Officer | Open Market Disposition | -131 | $82.81–105.60 |
| 2026-07-09 | Michael Fiore | Former Executive Vice President | Open Market Disposition | -2,354 | $95.00 |
| 2026-07-08 | Michael Gathright | -- | Sale to Issuer | -2,270 | $93.07 |
| 2026-07-07 | James Lucania | Chief Financial Officer | Sale to Issuer | -2,839 | $95.08 |
| 2026-07-07 | Stephen Neeleman | Founder & Vice Chairman | Sale to Issuer | -1,103 | $95.08 |
| 2026-07-07 | Scott Cutler | Chief Executive Officer | Sale to Issuer | -1,238 | $95.08 |
| 2026-07-07 | Delano Ladd | General Counsel | Sale to Issuer | -1,087 | $95.08 |
| 2026-07-07 | Michael Fiore | Former Executive Vice President | Sale to Issuer | -2,045 | $95.08 |
| 2026-07-01 | Michael Fiore | Former Executive Vice President | Automatic Disposition | -2,470 | $95.00 |
| 2026-06-24 | Adrian Dillon | Independent Director | Other Acquisition | +2,877 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
HealthEquity discussion 0 comments